Clinical trials: Diabetic Retinal Disease
Proliferative Diabetic Retinopathy
PRP vs Bevacizumab for PDR Treatment
Protocol S by DRCR.net has shown that receive Ranibizumab as anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard…
- Trial name
- NCT02705274
- Testing
- Bevacizumab, Panretinal photocoagulation
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Marashi Eye Clinic
Age-Related Macular Degeneration, Diabetic Retinopathy
Defining Retinal Structures Using Hyperspectral Retinal Imaging
This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease.
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Retinal Diseases
- Trial name
- NCT07555574
- Testing
- Hyperspectral camera
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Macular Degeneration, Diabetic Retinopathy (DR)
Artificial Intelligence-assisted Diagnosis in Ophthalmology
This is a retrospective, multicenter, observational study designed to develop and validate an artificial intelligence (AI) system capable of detecting and classifying major ophthalmic diseases (glaucoma, cataract, diabetic…
- Conditions
- Macular Degeneration, Diabetic Retinopathy (DR), Glaucoma, Keratoconus
- Trial name
- AI-OPHTH-CR (NCT07497815)
- Testing
- No interventions
- Where
- 2 sites in Costa Rica
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Marisse Masis-Solano
Diabetic Retinopathy
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
An online survey (n=1,500) and 4 focus groups will be conducted with Latinx patients with diabetes (n=20) to obtain preliminary data regarding whether and how patient and clinician video testimonial interventions (n=6) increase…
- Trial name
- NCT06257082
- Testing
- Online Survey
- Where
- United States
- Volunteers
- 1,526 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Non-proliferative Diabetic Retinopathy
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).
- Trial name
- NCT02388984
- Testing
- Compound danshen dripping pills
- Where
- 16 sites in China
- Volunteers
- 480 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Diabetic Kidney Disease, Diabetic Retinopathy
Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy
The purpose of the study is to evaluate the efficacy of Keluoxin Capsules for the treatment of diabetic kidney disease (DKD) and diabetic retinopathy (DR) compared to placebo on a conventional treatment basis.
- Trial name
- NCT06660940
- Testing
- Keluoxin Capsules, Keluoxin Capsule Simulants, Irbesartan
- Volunteers
- 460 people
- Sponsor
- Chinese PLA General Hospital
Macular Edema
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.
- Trial name
- NCT00782717
- Testing
- Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Nepafenac ophthalmic suspension vehicle, Prednisolone acetate ophthalmic suspension (OMNIPRED)
- Volunteers
- 263 people
- Sponsor
- Alcon Research
Proliferative Diabetic Retinopathy
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial growth factor (anti-VEGF) therapy with…
- Trial name
- Protocol S (NCT01489189)
- Testing
- Prompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
- Where
- 48 sites in United States
- Volunteers
- 305 people
- Sponsor
- Jaeb Center for Health Research
Retinal Disease, Retinal Detachment
High Resolution Optical Coherence Tomography
Comparison of high-resolution optical coherence tomography (High-Res-OCT) to conventional imaging modalities for the diagnosis of eye diseases
- Conditions
- Retinal Disease, Retinal Detachment, Retinal Vein Occlusion, Retinal Dystrophy
- Trial name
- NCT05130385
- Testing
- High-resolution optical coherence tomography (High-Res-OCT), Standard spectral domain OCT (SD-OCT)
- Where
- Switzerland
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00131144
- Testing
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- Novartis
Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy
Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy
The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes.
- Conditions
- Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy, Remote Ischemic Conditioning, Diabetes Mellitus, Type 2
- Trial name
- RIC-NPDR (NCT06713720)
- Testing
- Remote Ischemic Conditioning Device
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- Xuxiang Zhang, MD
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
Given the high number of people with DMO and PDR, the need for patients to be seen at short follow-up intervals, the need for frequent treatments and the requirement for long-term follow-up, there is a very large workload in…
- Trial name
- EMERALD (NCT03490318)
- Where
- 13 sites in United Kingdom
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Belfast Health and Social Care Trust
Macular Degeneration, Retinal Vein Occlusion
Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders.
- Trial name
- NCT00071227
- Testing
- Triamcinolone Acetonide (TAC-PF)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Eye Institute (NEI)
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
The purpose of this study was to determine the safety of ranibizumab: a) as a surgical adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR) induced rubeosis and, b) in treatment of…
- Trial name
- NCT01069341
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Bhagat, Neelakshi, M.D., M.P.H.
Macular Degeneration, Diabetic Macular Edema
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
The purpose of this study is to assess the sensation of ocular dry eye symptom after an intravitreal injection of anti-VEGF.
- Conditions
- Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- PISO (NCT06262737)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Diabetic Macular Edema, Diabetic Retinopathy
4D-150 in Patients With Diabetic Macular Edema
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
- Trial name
- NCT05930561
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- 4D Molecular Therapeutics
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.
Diabetic Retinopathy
Correlation Between HBA1c Level and Thickness of Both Macula and Choroid in Patients With Type 2 Diabetes Mellitus
Diabetic retinopathy (DR) is a frequent cause of visual impairment, and the leading cause of blindness in those of working age, but it develops silently along years, producing symptoms only in late stages.
- Trial name
- NCT05778370
- Testing
- Swept Source Optical Coherence Tomography(Topcon DRI Triton)
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Assiut University
Macular Edema, Macular Degeneration
Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
The study was designed to assess the efficacy and safety of Lucentis® (ranibizumab 0.5 mg) in diabetic patients presenting with reduced visual acuity due to diabetic macular edema and evaluating spacing out of follow-up after…
- Conditions
- Macular Edema, Macular Degeneration, Diabetes
- Trial name
- CONSTELLATION (NCT02032173)
- Testing
- Ranibizumab 0.5mg
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME).
- Trial name
- ALTITUDE® (NCT04567550)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3
- Where
- 25 sites in United States
- Volunteers
- 139 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.